Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a chemically synthesized compound, designed as an E3 ligase ligand-linker conjugate, integrating the cereblon ligand derived from Pomalidomide and a linker employed in PROTAC technology. This compound serves to facilitate targeted protein degradation through the modulation of E3 ligase activity, enabling the selective elimination of specific proteins of interest.
Lenalidomide-C5-NH2 is the Lenalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Lenalidomide-C5-NH2 can be connected to the ligand for protein by a linker to form PROTACs[1].
Lenalidomide-acetylene-C5-COOH (compound 43; Cereblon ligand-linker Conjugate) serves as a Lenalidomide-based Cereblon ligand that facilitates the recruitment of the CRBN protein. This compound can be connected to the protein's ligand through a linker, resulting in the formation of PROTAC[1].
NH2-C5-PEG4-N3-L-Lysine-PEG3-N3 is a seven-unit cleavable polyethylene glycol (PEG) antibody-drug conjugate (ADC) linker employed in the synthesis of ADCs[1].
Boc-C5-O-C5-O-C6-Cl (PROTAC Linker 2) is a chemical compound commonly employed as a linker in PROTAC applications. Its primary function is to connect a specific tyrosine kinase inhibitor (TKI) with the E3 recruiting ligand.
(S,R,S)-AHPC-amido-C5-acid is a chemical compound that contains a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. It can be utilized in the design of XY028-133[1].
(S,R,S)-AHPC-C5-COOH (VH032-C5-COOH) is a synthesized E3 ligase ligand-linker conjugate, contains the VH032 VHL-based ligand and a linker to form PROTACs. VH-032 is a selective and potent inhibitor of VHL HIF-1α interaction with a Kd of 185 nM, has the potential for the study of anemia and ischemic diseases[1].
(S,R,S)-AHPC-Me-C5-COOH is a synthetic E3 ligase ligand-linker conjugate consisting of a VHL ligand and a linker. It finds application in PROTAC DT2216[1].